Greystone, Over the next few months, many people will begin to comprehend just how enormous the opportunity is here. It’s human nature for people to not get excited and take a belief that winning big couldn’t happen to them.
But any doubters only need to re-listen to Dr Bradley Glovers presentation today. TURNING COLD TUMORS HOT! The holy grail of CarT therapy is to find a target for CarT on the surface of solid tumors.
IMU has done that. Not by identifying a target or protein on the surface. By infecting the cancer cells with a genetically modified cow pox virus which carries a CD19 antagonist. They have put the target on the outside. Thank you Sail Priceman.
The jobs done. They don’t need ALA’s Inkt technology. They don’t need anybody else’s CartT. IMU have the whole game wrapped up.
What oncologist is going to use Chemo once this gets it first approval. That’s where the value is here. 2025 Azer-Cel gets the FDA approval . 2025 Vaxinia gets its Fast Track Designation FDA marketing approval.
“ONCARLYTICS “ gets. Breakthrough Approval in 2025! It’s game over for chemo. Winner takes all.
$50 a share is a possibility here. And we’ll know very soon. But it sure smells like we’ve got this. Just watch the last 4 videos. The upcoming conference presentations. The recent peer review publications from Yuman Fong and team at CoH.
IMU Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
(20min delay)